Couldn’t make the Oxford Global’s 14th Annual Biomarkers Congress? Read our recap of the key opportunities and challenges in biomarker development that scientists discussed.
When assessing biomarkers for multifactorial diseases, we ideally want to assess multiple analytes in the same experiment. That is where the value of multiplex biomarker analysis comes in – but this method also inherently creates potential challenges with cross-reactivity. We discuss how the ProteinSimple Ella platform enables multiplexing with excellent assay reproducibility, and how it can benefit studies with low sample volumes.
Today we're featuring a case study on how BioAgilytix developed a cell-based assay to determine the prevalence of pre-existing antibodies against the AAV9 serotype in patients for a gene therapy clinical trial.
We find it critical to stay on top of the latest industry developments to inform our own work and help our customers best address emerging bioanalytical challenges and opportunities; we've compiled some of our favorite recent industry articles of interest to share with you.
In this Q&A session we talk to David Rusnak, one of the first 3 employees to join BioAgilytix when it was founded 10 years ago and currently our Director of Laboratory Systems and Automation, to learn more about his experience growing with the organization from its very start – and what still keeps him excited to come to work each day.
The FDA has observed an unprecedented increase in the number of cell and gene therapy products entering the early stages of development. In a recent statement, the agency outlined new planned policies to help accelerate these innovations through the pipeline to clinical success. We discuss what this announcement means to sponsors.
In this Q&A session, we speak to longtime BioAgilytix Europe team member Gabi Schewe – who has been with the company since its founding as IPM Biotech in 1996 – to hear about the exciting and historic scientific advancements she has been part of with the company and what she believes has made its long-term success possible.
Consistent discussion and improvement upon the standard practices of bioanalytical laboratories is critical to improving the work we do supporting innovative biologics development in the long-term. One of the rapidly advancing areas that is being regularly discussed in the industry is the evolution of ligand-binding assay (LBA) platforms. In this blog, I will summarize best practices and characteristics associated with LBA platforms as well as the features these platforms absolutely need to enable scientists to respond to industry pressures that drive demand for increasingly complex bioanalysis, condensed timelines, and continued…
In this Q&A session, Soubhik Banerjee, Director of Business Development at BioAgilytix Europe, talks about BioAgilytix’s approach to collaboration and the impact it has had on his work since joining the team a few months ago.
BioAgilytix Europe's Arno Kromminga fielded some excellent questions from attendees of his recent immunogenicity webinar. He recaps and expands upon several of those answers in our latest blog
Services
Platforms
